TMP1

TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM) /TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM) . TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903) . TMP1 can be used in coronavirus research[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV; Ser/Thr Protease; Virus Protease

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C(C([C@H](NC([C@@H]1C[C@H](CN1C([C@H](C2CCCCC2)NC(C3CCC(F)(CC3)F)=O)=O)F)=O)CC4=CC=CC=C4)=O)NCC5=NC=C(C=C5)Cl

Molecular Formula

C36H43ClF3N5O5

Molecular Weight

718.21

References & Citations

[1]Chu H, et al. An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. Res Sq [Preprint]. 2024 Nov 21:rs.3.rs-5454588. doi: 10.21203/rs.3.rs-5454588/v1. Update in: Nat Commun. 2025 Jul 16;16 (1) :6541.